<DOC>
	<DOC>NCT02566031</DOC>
	<brief_summary>To demonstrate superiority of QVA149 (110/50 μg) once daily compared to tiotropium 18 μg once daily in terms of trough forced expiratory volume in 1 second (FEV1) (mean of 45 min and 15 min pre-dose) following 12 weeks of treatment in mild to moderate symptomatic COPD patients</brief_summary>
	<brief_title>A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Confirmed diagnosis of COPD and postbronchodilator FEV1 ≥ 50% of the predicted normal value and postbronchodilator FEV1/FVC &lt; 0.7 (COPD Grade 1 or 2 by severity of airflow limitation (GOLD 2015) Patients with CAT score ≥ 10 at Visit 0 and Visit 1. Patients who are on and have been on tiotropium monotherapy for the past 3 months. 0 or 1 COPD exacerbation in the previous 12 months (not leading to hospital admission). Treatment with any inhaled corticosteroid (ICS) in the 3 months prior to Visit 1. COPD exacerbation between Visit 0 and 1. Patients with concomitant pulmonary disease Patients with a history of respiratory infection within 4 weeks prior to Visit 0. Prior or current diagnosis of asthma. Presence of any contraindication, warning, precaution, hypersensitivity to LABA and LAMA Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>open-label</keyword>
	<keyword>QVA149</keyword>
	<keyword>symptomatic</keyword>
	<keyword>tiotropium</keyword>
</DOC>